GLP-1, Weight Regain, and the WHO: What “Progressive and Relapsing” Actually Means
When the World Health Organization released its first-ever global GLP-1 guidelines this month, most of the conversation focused on access.
Who qualifies.
Whether insurance will follow.
What this means for prescribing.
That’s what headlines do.
I did what I always do. I read the actual guidance.
And one sentence stopped me cold.
The WHO describes obesity as a chronic, progressive, and relapsing disease.
Not just chronic.
Not just complex.
Progressive.
Relapsing.
Those words matter more than most people realize.
What Actually Changed — and When
Here’s the part that got missed.
On December 1, 2025, the WHO released global guidelines on the use of GLP-1 medications for obesity. Throughout the document, obesity is repeatedly described as a chronic, progressive, and relapsing disease requiring long-term care.
A week later, the WHO updated its public-facing obesity fact sheet. For the first time, the word relapsing appeared in how obesity is defined for the general public.
Before this update, public definitions were far more limited.
The CDC still defines obesity as “a common, serious, and costly chronic disease.”
Chronic — but not progressive.
Chronic — but not relapsing.
That difference isn’t semantic. It’s foundational.
Why This Wasn’t Headline News
If you followed doctors or medical creators when the guidelines were released, you probably noticed the same thing I did.
The focus was on:
- GLP-1 being endorsed for long-term use
- Treatment frameworks
- Policy implications
Almost no one talked about the words progressive or relapsing.
That’s not because they’re unimportant.
It’s because they’re already normalized inside clinical spaces.
Medical organizations have used this language for years. The World Obesity Federation formally described obesity as a chronic, relapsing, progressive disease back in 2017.
For clinicians, this framing isn’t new.
For patients, it is.
The Gap No One Prepared You For
Most women have spent their lives being told some version of the same story.
That obesity is:
- a lifestyle issue
- a willpower problem
- something you fix, then move on from
Even when the word chronic is used, it’s rarely explained.
What hasn’t been said plainly is this:
A progressive disease doesn’t stabilize on its own. It continues to advance if it isn’t actively managed.
A relapsing disease doesn’t stay “solved” once weight is lost — not only if treatment stops, but if you assume the problem is fixed and stop making deliberate, daily decisions that protect your health.
Seeing those words written clearly — and publicly — changes how you understand what you’re managing.
What “Relapsing” Actually Means
Relapsing describes how the condition behaves over time.
It means weight regain is an expected risk when any part of the system changes — medication use, age, hormonal transitions like menopause or pregnancy, new or worsening medical conditions, mental health strain, major life events, or periods when attention, structure, or capacity are stretched.
This isn’t a moral statement. It’s a description of how biology responds to changing inputs.
Relapsing means obesity doesn’t remain “solved” simply because weight has been lost. It requires continued, deliberate management, the same way other long-term conditions do.
What’s new for many women isn’t the idea of relapse itself. It’s the realization that health isn’t a one-time achievement.
For women who have spent most of their lives overweight, it’s easy to believe that being “healthy” is something other people are — naturally. As if one day you cross a line, fix the problem, and arrive.
In reality, the people who appear effortlessly healthy are usually making consistent, ordinary decisions in favor of their health every day — about food, movement, rest, and structure. Not perfectly. Repeatedly.
This is how long-term conditions behave over time.
What “Progressive” Changes About Delay
Progressive means the condition worsens without intervention.
It doesn’t wait politely while life is busy.
It doesn’t pause because intentions are good.
This matters for women who delay care, minimize need, or hope things will self-correct.
Progression isn’t about blame. It’s about reality.
Support earlier is often less disruptive than support later.
Why This Reframe Matters for GLP-1
GLP-1 medications such as Zepbound, Wegovy, Mounjaro, and Ozempic didn’t create the relapsing nature of obesity. Obesity as a relapsing disease was established years before GLP-1 was used as a treatment for obesity.
There isn’t a new risk of regain.
Regain has always been part of the condition.
This isn’t just about what happens if you stop medication — even though that is now more explicit than ever.
No matter the path used to lose weight, obesity involves ongoing risk of relapsing.
Without an updated understanding of the disease itself, many women build plans that assume:
- a clean finish line
- a future without continued treatment or effort
- an eventual exit from medication
The WHO guidance quietly but powerfully challenges those assumptions.
Long-term care reflects how the condition is managed over time. The strategy has to match the condition.
What the WHO Says Effective Care Requires
Another section of the guidance makes this explicit.
The WHO states that effective obesity care must go far beyond weight reduction alone and include:
- pharmacotherapy when appropriate
- behavior change support
- long-term follow-up
- supportive environments
Medication is part of care.
It isn’t the entire plan.
This isn’t extra work. It’s the work.
Why This Perspective Matters
I’m not a medical professional. But I have lived, studied, and worked close enough to medicine to understand how the system thinks — and I now coach from the perspective of lived patient experience.
That places me in a position to notice what often gets skipped between those worlds.
Clinical language carries assumptions. When those assumptions aren’t translated, people fill in the gaps with urgency, confusion, or unrealistic expectations.
This WHO guidance did more than validate GLP-1 as an effective treatment.
It clarified how obesity is understood medically — in a way many people outside the clinical world were never taught to see.
It made an existing truth visible.
And visibility changes how women plan, structure their lives, and approach this journey long-term.
What This Changes About How You Move Forward
Once you understand obesity as chronic, progressive, and relapsing, the question is no longer:
“When will I get to goal weight?”
It quietly becomes:
“How do I live like this long-term — without burning out or white-knuckling it?”
Because for most women on GLP-1, the mental loop looks something like this:
- “When I get to my goal weight, things will feel easier.”
- “Skipping meals here and there is fine if the scale is moving. I’ll get consistent once I’ve lost enough.”
- “Eventually this won’t take so much attention. It’ll just start to feel routine.”
Those assumptions make sense — especially if you’ve spent your life believing that healthy people are just naturally healthy.
But what the WHO language makes clear is this:
There is no moment where attention is no longer required.
There is no version of health that runs itself.
The women who appear stable over time aren’t relying on willpower or motivation.
They’ve built lives where health decisions are defaulted, not debated.
They don’t wake up asking:
“Should I eat in a way that supports my health today?”
“Should I move my body?”
“Should I take care of myself?”
Those decisions are already made — structurally.
So the more useful questions now become:
“What parts of my current approach wouldn’t hold up long-term?”
“What happens to my eating, movement, or overall wellbeing when life gets busy, stressful, or unpredictable?”
“Am I building skills and systems that will guide me for life — or just pushing through this phase?”
This isn’t about doing more.
It’s about designing your life in a way that assumes:
- seasons will change
- capacity will fluctuate
- your body will respond to those changes
That’s the difference between chasing an end point — and building something that holds.
And that’s exactly the work we begin inside The GLP-1 Strategy Lab Waitlist — for high achieving, where we focus on building the systems most women wish they had put in place earlier in their journey, the strategy to get the most out of each dose and the mindset for success on the shot.
If this post helped something click, this is where we turn that clarity into structure. Follow the pink button below.
References:
- World Health Organization. Guideline on the use of GLP-1 medicines for the treatment of obesity in adults. December 1, 2025.
- World Health Organization. Obesity and Overweight Fact Sheet. Updated December 8, 2025.
- Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. Obesity Reviews. 2017.
One Response